Funding for this research was provided by:
National Institute on Drug Abuse (R33DA035641)
National Center for Advancing Translational Sciences (UL1TR000117)
Received: 13 March 2017
Accepted: 6 August 2017
First Online: 16 August 2017
Ethics approval and consent to participate
: All study procedures conformed to the Declaration of Helsinki. The study was approved by the Institutional Review Board of the University of Kentucky (Protocol 13–0068-P6J). Before the qualitative interviews, individuals were sent information regarding their rights as research subjects and verbal informed consent to participate and be recorded was obtained before the start of the interview. Individuals participating in the survey provided written informed consent.
: All participants consented to their data being included in publications, provided that identifying information was not published.
: HK, JC, and JLS declare they have no competing interests. MRL has received contract research funding from Braeburn Pharmaceuticals, has provided consultation for Indivior, and has received honoraria from PCM Scientific, which received unrestricted educational grant funds from Reckitt Benckiser (now Indivior, which manufactures the buprenorphine product, Suboxone®) for the development and delivery of educational talks on opioid dependence. SLW has received research support and consulting fees from Braeburn Pharmaceuticals, consulting fees from Camurus, and honoraria from PCM Scientific, through an arms-length unrestricted educational grant from Reckitt Benckiser, as a speaker and organizer of conferences. JRH has received honoraria from Pinney Associates for her service on an external advisory board examining buprenorphine abuse and diversion.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.